To order this 540+ page report, which features 175+figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html
KeyMarket Insights
§ More than 40 large volume wearable injectors are presentlyavailable / under development for the administration of drugs, beyond insulin, including15+ drug device combinations
§ Companies focused on developing devices for the delivery ofinsulin have already established strong brand positions in this domain, with 30+devices currently under development or available
§ More than 200 biologics / small molecule drugs wereidentified as likely products to be developed in combination with large volumewearable injectors
§ The rising interest in this fieldis reflected in the number of partnerships (90+) inked between 2015
and 2020 (tillJune), involving both international and indigenous stakeholders, across theworld
§ An evaluation of 50+ stakeholders engaged in thedevelopment of large volume wearable injectors revealed the existence ofseveral likely acquisition targets, across different geographical regions
§ The market, for the large volumewearable injectors for the delivery of non-insulin drugs is projected to be worth USD 600 million; owingto the increasing incidence of chronic clinical conditions and growing pipelineof therapeutic interventions to treat such diseases
§ The large volume wearable injectors market for insulin isanticipated to be worth over USD 2.7 billion by 2030; the anticipatedopportunity is likely to be distributed across various different device types,therapeutic areas and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. An Overviewof Drug Delivery Devices
3.3. ConventionalParenteral Drug Delivery
3.3.1 Needlestick Injuries
3.4. Emergenceof Self-Administration Devices
3.4.1. DrivingFactors
3.5. AvailableSelf-Injection Devices
3.5.1. PrefilledSyringes
3.5.2. Pen-Injectors
3.5.3. Needle-FreeInjectors
3.5.4. Autoinjectors
3.5.5. Large VolumeWearable Injectors
3.6. RegulatoryConsiderations
3.6.1. MedicalDevices
3.6.2. Drug DeviceCombination Products
3.7. FuturePerspectives of Self-Injection Systems
4. LARGE VOLUME WEARABLE INJECTORS:CURRENT MARKET LANDSCAPE
4.1. ChapterOverview
4.2. LargeVolume Wearable Injectors: Overall Market Landscape
4.2.1. Large VolumeWearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Analysis by Stage of Development
4.2.1.2. Analysis by Type of Device
4.2.1.3. Analysis by Type of Dose
4.2.1.4. Analysis by Route of Administration
4.2.1.5. Analysis by Mode of Injection
4.2.1.6. Analysis by Volume / Storage Capacity
4.2.1.7. Analysis by Actuation Mechanism
4.2.1.8. Analysis by Usability
4.2.1.9. Analysis by Availability of Prefilled DrugReservoir
4.2.1.10.Analysis by Availability of Connectivity
4.2.2. Large Volume Drug Device Combinations:Market Landscape
4.2.2.1. Analysis by Stage of Development
4.2.2.2. Analysis by Type of Device
4.2.2.3. Analysis by Drug Compatibility
4.2.2.4. Analysis by Type of Dose
4.2.2.5. Analysis by Route of Administration
4.2.2.6. Analysis by Mode of Injection
4.2.2.7. Analysis by Therapeutic Area
4.2.2.8. Analysis by Volume / Storage Capacity
4.2.2.9. Analysis by Usability
4.2.3. Large Volume Wearable Injectors for Non-InsulinDrugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Analysis by Year of Establishment
4.2.3.2. Analysis by Company Size
4.2.3.3. Analysis by Geography
4.2.4. Large Volume Wearable Injectors for Insulin:Market Landscape
4.2.4.1. Analysis by Stage of Development
4.2.4.2. Analysis by Type of Device
4.2.4.3. Analysis by Volume / Storage Capacity
4.2.4.4. Analysis by Usability
4.2.4.5. Analysis by Availability of Prefilled InsulinCartridges
4.2.4.6. Analysis by Availability of CGM / BGM System
4.2.4.7. Analysis by Availability of Automated InsulinDelivery (AID) Feature
4.2.4.8. Analysis by Availability of Connectivity
4.2.4.9. Analysis by Type of Remote Control Features
4.2.5. Large Volume Wearable Injectors forInsulin: Analysis of Developers
4.2.5.1. Analysis by Year of Establishment
4.2.5.2. Analysis by Company Size
4.2.5.3. Analysis by Geography
5. PRODUCTCOMPETITIVENESS ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptions/ Key Parameters
5.4. ProductCompetitiveness Analysis
5.4.1. Large VolumeWearable Injectors for Non-Insulin Drugs
5.4.2. Large VolumeDrug Device Combinations
5.4.3. Large VolumeWearable Injectors for Insulin
6. LARGEVOLUME WEARABLE INJECTORS: KEY PLAYERS
6.1. Chapter Overview
6.2. LargeVolume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. BectonDickinson
6.2.1.1. Company Snapshot
6.2.1.2. Financial Information
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bespak
6.2.2.1. Company Snapshot
6.2.2.2. Financial Information
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Enable Injections
6.2.3.1. Company Snapshot
6.2.3.2. Product Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Insulet
6.2.4.1. Company Snapshot
6.2.4.2. Financial Information
6.2.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Roche
6.2.5.1. Company Snapshot
6.2.5.2. Financial Information
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Sensile Medical
6.2.6.1. Company Snapshot
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.2.7. Sonceboz
6.2.7.1. Company Snapshot
6.2.7.2. Product Portfolio
6.2.7.3. Recent Developments and Future Outlook
6.2.8. SteadyMed Therapeutics
6.2.8.1. Company Snapshot
6.2.8.2. Product Portfolio
6.2.8.3. Recent Developments and Future Outlook
6.2.9. Weibel CDS
6.2.9.1. Company Snapshot
6.2.9.2. Product Portfolio
6.2.9.3. Recent Developments and Future Outlook
6.2.10. West Pharmaceutical Services
6.2.10.1.Company Snapshot
6.2.10.2.Financial Information
6.2.10.3.Product Portfolio
6.2.10.4.Recent Developments and Future Outlook
6.3. Large Volume Wearable Injectors forInsulin: Key Players
6.3.1. CeQur
6.3.1.1. Company Snapshot
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Debiotech
6.3.2.1. Company Snapshot
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Eli Lilly
6.3.3.1. Company Snapshot
6.3.3.2. Financial Information
6.3.3.3. Product Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medtronic
6.3.4.1. Company Snapshot
6.3.4.2. Financial Information
6.3.4.3. Product Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.3.5. PharmaSens
6.3.5.1. Company Snapshot
6.3.5.2. Product Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. SOOIL Development
6.3.6.1. Company Snapshot
6.3.6.2. Product Portfolio
6.3.6.3. Recent Developments and Future Outlook
6.3.7. Tandem Diabetes Care
6.3.7.1. Company Snapshot
6.3.7.2. Financial Information
6.3.7.3. Product Portfolio
6.3.7.4. Recent Developments and Future Outlook
7. DRUG-DEVICECOMBINATIONS: TABULATED PROFILES
7.1. ChapterOverview
7.2. Apomorphine /D-mine® Pump
7.3. Apomorphine /ND0701
7.4. Bupivacaine /SMT-301
7.5. Ceftriaxone /sc2Wear® Infusor
7.6. Furosemide / 3mL Micropump
7.7. Furosemide /FUROSCIX® On-body Infusor
7.8. Herceptin® / SingleUse Injector
7.9. Ketorolac /SMT-201
7.10. Levodopa andCarbidopa / ND0612 and ND0901
7.11. Lutrepulse /The LUTREPULSE® System
7.12. Neulasta® /Neulasta OnPro™ On-body Injector
7.13. Repatha® /Pushtronex® System
7.14. Treprostinil /Trevyent®
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Large Volume Wearable Injectors: List ofPartnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Device
8.3.4. Analysis by Year of Partnership and Type ofPartner
8.3.5. Most Active Players: Analysis by Number ofPartnerships
8.3.6. Regional Analysis
8.3.7. Intercontinental and IntracontinentalAgreements
9. KEY ACQUISITION TARGETS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Potential Strategic Acquisition Targetsfor Non-Insulin Drug Delivery Players
9.5. Potential Strategic Acquisition Targetsfor Insulin Drug Delivery Players
9.6. Concluding Remarks
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: PatentAnalysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Issuing Authority / Patent OfficesInvolved
10.3.3. Analysis by CPC Symbols
10.3.4. Emerging Focus Areas
10.3.5. Analysis by Type of Organization
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Large Volume Wearable Injectors: PatentBenchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Large Volume Wearable Injectors: PatentValuation Analysis
11. LARGE VOLUME WEARABLE INJECTORS: LIKELYDRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs
11.2.1. Most Likely Candidates for Delivery via LargeVolume Wearable Injectors
11.2.2. Likely Candidates for Delivery via LargeVolume Wearable Injectors
11.2.3. Less Likely Candidates for Delivery via LargeVolume Wearable Injectors
11.2.4. Unlikely Candidates for Delivery via LargeVolume Wearable Injectors
11.3. Clinical Drug Candidates
11.3.1. Biologics
11.3.1.1. Most LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.2. LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.3. Less LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.4. UnlikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2. SmallMolecules
11.3.2.1. Most LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.2. LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.3. Less LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.4. UnlikelyCandidates for Delivery via Large Volume Wearable Injectors
12. EMERGING TRENDS ON SOCIAL MEDIA
12.1. Chapter Overview
12.2. Large Volume Wearable Injectors: Trends onTwitter
12.2.1. Historical Trend in Volume of Tweets
12.2.2. Trending Words / Phrases Related to LargeVolume Wearable Injectors
12.2.3. Most Influential Authors
12.2.4. Popular Players on Twitter
12.2.4.1. Roche (ACCU-CHEK®Solo Micropump System)
12.2.4.2. Insulet(Omnipod®)
12.2.4.3. Medtronic(MiniMed® Wearable Injectors)
12.2.4.4. Comparisonof Popular Players Based on Number of Tweets
12.3. Concluding Remarks
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Large Volume Wearable Injectors: ClinicalTrial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Trial Registration and Number ofPatients Enrolled
13.3.5. Analysis by Study Design
13.3.6. Analysis by Type of Sponsor / Collaborator
13.3.7. Leading Players: Analysis by Number ofRegistered Trials
13.3.8. Word Cloud: Key Focus Areas
13.3.9. Analysis by Therapeutic Area
13.3.10. PopularDrug Device Combinations: Analysis by Number of Registered Trials
13.3.11. GeographicalAnalysis by Number of Registered Trials
13.3.12. GeographicalAnalysis by Patients Enrolled
13.3.13. Analysis byClinical Endpoints
14. CASE STUDY: ROLE OF CMOs IN DEVICEDEVELOPMENT SUPPLY CHAIN
14.1. Chapter Overview
14.2. Device Development Supply Chain
14.3. Significance of CMOs in the Drug DeliveryDevice Development Process
14.4. List of Contract ManufacturingOrganizations
14.4.1. Contract Manufacturers: GeographicalDistribution and Services Offered
15. REGULATORY AND REIMBURSEMENT LANDSCAPEFOR MEDICAL DEVICES
15.1. ChapterOverview
15.2. GeneralRegulatory and Reimbursement Guidelines for Medical Devices
15.3. Regulatoryand Reimbursement Landscape in North America
15.3.1. The USScenario
15.3.2. The Canadian Scenario
15.3.3. The Mexican Scenario
15.4. Regulatoryand Reimbursement Landscape in Europe
15.4.1. OverallScenario
15.4.1.1. OverallRegulatory Authority
15.4.1.2. OverallReview / Approval Process
15.4.2. The UKScenario
15.4.3. The FrenchScenario
15.4.4. The GermanScenario
15.4.5. The ItalianScenario
15.4.6. The SpanishScenario
15.5. Regulatoryand Reimbursement Landscape in Asia-Pacific and Rest of the World
15.5.1. TheAustralian Scenario
15.5.2. TheBrazilian Scenario
15.5.3. The ChineseScenario
15.5.4. The IndianScenario
15.5.5. The IsraeliScenario
15.5.6. TheJapanese Scenario
15.5.7. The NewZealand Scenario
15.5.8. TheSingaporean Scenario
15.5.9. The SouthKorea Scenario
15.5.10. The SouthAfrican Scenario
15.5.11. TheTaiwanese Scenario
15.5.12. TheThailand Scenario
15.6. Comparison of Regional RegulatoryEnvironment
15.7. Concluding Remarks
16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Global Large Volume Wearable InjectorsMarket for Non-Insulin Drugs, 2020-2030 (By Value)
16.3.1. Global Large Volume Wearable Injectors Marketfor Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Value)
16.3.2 Global Large Volume Wearable Injectors Marketfor Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Value)
16.3.3 Global Large Volume Wearable InjectorsMarket for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (ByValue)
16.4 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America, 2020-2030 (By Value)
16.4.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030(By Value)
16.4.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (ByValue)
16.4.3 Large Volume Wearable Injectors Marketfor Non-Insulin Drugs in North America: Distribution by Therapeutic Area,2020-2030 (By Value)
16.5 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe, 2020-2030 (By Value)
16.5.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (ByValue)
16.5.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Value)
16.5.3 Large Volume Wearable Injectors Marketfor Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030(By Value)
16.6 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.6.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (ByValue)
16.6.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (ByValue)
16.6.3 Large Volume Wearable Injectors Marketfor Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area,2020-2030 (By Value)
16.7. Global Large Volume Wearable InjectorsMarket for Non-Insulin Drugs, 2020-2030 (By Volume)
16.7.1. Global Large Volume Wearable Injectors Marketfor Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Volume)
16.7.2 Global Large Volume Wearable Injectors Marketfor Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Volume)
16.7.3 Global Large Volume Wearable InjectorsMarket for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (ByVolume)
16.8 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America, 2020-2030 (By Volume)
16.8.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030(By Volume)
16.8.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (ByVolume)
16.8.3 Large Volume Wearable Injectors Marketfor Non-Insulin Drugs in North America: Distribution by Therapeutic Area,2020-2030 (By Volume)
16.9 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe, 2020-2030 (By Volume)
16.9.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (ByVolume)
16.9.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Volume)
16.9.3 Large Volume Wearable Injectors Marketfor Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030(By Volume)
16.10 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.10.1 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030(By Value)
16.10.2 Large Volume Wearable Injectors Market forNon-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (ByValue)
16.10.3 Large Volume WearableInjectors Market for Non-Insulin Drugs in Asia Pacific: Distribution byTherapeutic Area, 2020-2030 (By Value)
16.11. Global Large Volume Wearable Injectors Marketfor Insulin, 2020-2030
16.11.1 Global Large Volume Wearable Injectors Marketfor Insulin: Distribution by Type of Device, 2020-2030
16.11.2 Global Large Volume Wearable Injectors Marketfor Insulin: Distribution by Usability, 2020-2030
16.12 Large Volume Wearable Injectors Market forInsulin in North America, 2020-2030
16.12.1 Large Volume Wearable Injectors Market forInsulin in North America: Distribution by Type of Device, 2020-2030
16.12.2 Large Volume Wearable Injectors Market forInsulin in North America: Distribution by Usability, 2020-2030
16.13 Large Volume Wearable Injectors Market forInsulin in Europe, 2020-2030
16.13.1 Large Volume Wearable Injectors Market forInsulin in Europe: Distribution by Type of Device, 2020-2030
16.13.2 Large Volume Wearable Injectors Market forInsulin in Europe: Distribution by Usability, 2020-2030
16.14 Large Volume Wearable Injectors Market forInsulin in Asia Pacific, 2020-2030
16.14.1 Large Volume Wearable Injectors Market forInsulin in Asia Pacific: Distribution by Type of Device, 2020-2030
16.14.2 Large Volume Wearable Injectors Market forInsulin in Asia Pacific: Distribution by Usability, 2020-2030
17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. SWOT Analysis
17.2.1. Strengths
17.2.2. Weaknesses
17.2.3. Opportunities
17.2.4. Threats
17.3. Large Volume Wearable Injectors: FutureGrowth Opportunities
17.3.1. Rising Focus on Self-Administration of Drugs
17.3.2. Possibility of Integration with MobileApplications
17.3.3. Potential Life Cycle Management Tool
17.3.4. Potential Usability for Multiple TherapeuticAreas
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Subcuject
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Jesper Roested, ChiefExecutive Officer (Q2 2020)
18.3. Sorrel Medical
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Mindy Katz, Director ofProduct (Q2 2020)
18.4. Medipacs
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Mark Banister, ChiefExecutive Officer (Q3 2016)
18.5. Elcam Medical
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Menachem Zucker, VicePresident and Chief Scientist (Q3 2016)
18.6. West Pharmaceutical Services
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Graham Reynolds, VicePresident and General Manager, Biologics (Q3 2016)
18.7. Enable Injections
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Michael Hooven, ChiefExecutive Officer (Q3 2014)
18.8. scPharmaceuticals
18.8.1. Company Snapshot
18.8.2. InterviewTranscript: Pieter Muntendam, former President and Chief Executive Officer (Q3 2014)
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
